A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors ; volume:97 ; number:2 ; year:2019 ; pages:102-111
Oncology ; 97, Heft 2 (2019), 102-111

Creator: Hong, David
Rasco, Drew
Veeder, Michael
Luke, Jason J.
Chandler, Jason
Balmanoukian, Ani
George, Thomas J.
Munster, Pamela
Berlin, Jordan D.
Gutierrez, Martin
Mita, Alain
Wakelee, Heather
Samakoglu, Selda
Guan, Shanhong
Dimery, Isaiah
Graef, Thorsten
Borazanci, Erkut

DOI: 10.1159/000500571

URN: urn:nbn:de:101:1-2019081500400994578182

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hong, David
Rasco, Drew
Veeder, Michael
Luke, Jason J.
Chandler, Jason
Balmanoukian, Ani
George, Thomas J.
Munster, Pamela
Berlin, Jordan D.
Gutierrez, Martin
Mita, Alain
Wakelee, Heather
Samakoglu, Selda
Guan, Shanhong
Dimery, Isaiah
Graef, Thorsten
Borazanci, Erkut

Other Objects (12)

Ibrutinib and novel BTK inhibitors in clinical development

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)

Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Ibrutinib and novel BTK inhibitors in clinical development

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)

Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Ibrutinib and novel BTK inhibitors in clinical development

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)

Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Ibrutinib and novel BTK inhibitors in clinical development

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)

Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Ibrutinib and novel BTK inhibitors in clinical development

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)

Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Ibrutinib and novel BTK inhibitors in clinical development

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Tumorzellspezifisches Targeting von Ibrutinib: Einführung von elektrostatischen Antikörper‐Inhibitor‐Konjugaten (AiCs)

Tumor‐Cell‐Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody‐Inhibitor Conjugates (AiCs)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Related objects

Reset password